Bell Potter says the departure of two healthcare analysts before Christmas will not lead to a watering down of its research business as one of Australia’s largest stockbrokers and financial advisers.
The firm that boasts $55 billion in funds under advice has suspended coverage of Atomo Diagnostics, Genetic Signatures, Immutep, Medical Developments, Opthea, Neuren, Starpharma, Pharmaxis and Pacific Smiles following the departure of veteran analyst Tanushree Jain in December for a research role at Petra Capital.
Loading...
Tom Richardson writes and comments on markets including equities, debt, crypto, software, banking, payments, and regulation. He worked in asset management at Bank of New York Mellon and is a member of the CFA Society of the UK as a holder of the Investment Management Certificate. Connect with Tom on Twitter. Email Tom at tom.richardson@afr.com
